Regenerex Pharma's ROA from the second quarter of 2025 to the second quarter of 2024 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Regenerex Pharma's ROA in the second quarter of 2025?
Regenerex Pharma, Inc. recorded a cumulative net loss of $-1 million during 12 months ending in the second quarter of 2025, resulting in a negative return on assets (ROA) of -213.31%.

However, within the Healthcare sector REGENEREX PHARMA, INC. achieved the highest return on assets. While Return on assets, overall ranking has advanced in the Sep 30 2025 quarter, so far to 4567, from total ROA ranking in the first quarter of 2025 at 4573.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Sep 30 2025) II. Quarter	(Jun 30 2025) I. Quarter	(Mar 31 2025) IV. Quarter	(Dec 31 2024) III. Quarter	(Sep 30 2024) II. Quarter
Y / Y Total Assets Change	8480.56 %	7034.58 %	19.46 %	106.32 %	-75.84 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-1	-1	-1	-4	-4
Return On Assets (TTM)	-213.31 %	-221.26 %	-228.95 %	-1279.68 %	-1284.84 %
RGPX's Total Ranking	# 4567	# 4573	# 4487	# 5638	# 5010
Total Assets (TTM) in million	1	1	1	0	0
Seq. Total Assets Change	-19.07 %	-39.57 %	3122.45 %	444.44 %	-32.71 %
Seq. Net Income Change	-	-	-	-	-

RGPX's 5 Years Annual ROA >> Back to RGPX Management Effectiveness >> Compare RGPX ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	#
Sector	#
Overall	# 0

Return On Assets Statistics
High	Average	Low
31428.57 %	625.23 %	-2246.15 %
(Mar 31 2023)		(Feb 28 2014)

Financial Statements
Regenerex Pharma's Assets	$ 1 million	RGPX's Balance sheet
Regenerex Pharma's Income	$ -1 million	Quarterly RGPX's Income Statement
RGPX's Income by Division		See RGPX's Income by Division

Annual Return On Assets	(Mar 31 2025) FY 2023	(Mar 31 2022) FY 2022	(Mar 31 2021) FY 2020	(Mar 31 2020) FY 2019	(Mar 31 2019) FY 2018
Y / Y Total Assets Change	550.06 %	2936.84 %	-95.48 %	-52.31 %	49.24 %
Total Assets in million	2	0	0	0	1
Y / Y Net Income Change	-	-	217.03 %	19.23 %	88.33 %
Net Income in million	-3	0	0	0	0
Annual Return On Assets	-112.29 %	-56.5 %	3103.51 %	44.22 %	17.69 %

RGPX's 5 Years Annual ROA >> Back to RGPX Management Effectiveness >> Compare RGPX ROA to its Competitors

More Return On Assets Ratios
RGPX's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
RGPX's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for RGPX's Competitors
Subscribers only: Roa for Regenerex Pharma's Suppliers
Subscribers only: Return On Assets for RGPX's Customers

You may also want to know
RGPX's Roi	RGPX's Inventory Turnover Ratio	RGPX's Growth Rates	RGPX's Dividend Comparisons
	RGPX's Profitability Ratios	RGPX's Asset Turnover Ratio	RGPX's Dividend Growth
RGPX's Roe	RGPX's Valuation Ratios	RGPX's Financial Strength Ratios	RGPX's Dividend Payout Ratio

Companies with similar Return On Assets at Sep 30 2025, within Healthcare Sector

ROA

Date modified: 2026-09-12T06:28:46+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.